Spinal muscular atrophy is a rare, genetic disease that causes severe muscle atrophy and weakness in infants and children. Ongoing mid-stage studies are showing that the drug increases muscle function in those suffering from the disease.
Isis currently enrolling infants with the disease in a phase 3 study, and it plans to begin a second phase 3 study of children with SMA later this year, according to the report.
More articles on devices:
37 spine, orthopedic devices receive FDA 510(k) clearance in September
Nevro files IPO — 6 things to know
BD buys CareFusion for $12.2B: 8 things to know
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
